Shares of Tvardi Therapeutics TVRD nosedived 83.9% on Monday after the company provided a disappointing update following an ...

Beyond its initial phase II trial results, stroke therapy developer Argenica has identified a clear path forward based on new ...

The BoE designed its test to understand how interactions between banks and non-banks could amplify market shocks and threaten ...

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

The IMF’s latest intervention underscores the growing concern that non-bank risks are migrating beyond the reach of ...

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...

Tvardi Therapeutics shares were 30% lower, at $7.19, in premarket trading after the company said its phase 2 study for TTI-101 didn't meet its goals. TTI-101 is a small molecule therapy targeting ...

In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...

Shares of Tvardi Therapeutics (NASDAQ:TVRD) dropped 30% on Monday after the company released weak preliminary results from ...

With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...

In a groundbreaking study using Merino sheep, researchers uncovered that tiny genetic variations within gut microbes can ...